Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...

Full description

Bibliographic Details
Main Authors: Anna Jamroz-Wiśniewska, Radosław Zajdel, Agnieszka Słowik, Monika Marona, Marcin Wnuk, Monika Adamczyk-Sowa, Bożena Adamczyk, Anetta Lasek-Bal, Przemysław Puz, Arkadiusz Stęposz, Ewa Krzystanek, Maja Patalong-Ogiewa, Anna Pokryszko-Dragan, Sławomir Budrewicz, Dorota Koziarska, Anna Karbicka, Sławomir Wawrzyniak, Waldemar Fryze, Marzena Furtak-Niczyporuk, Konrad Rejdak
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
relapsing-remitting type of multiple sclerosis
no evidence of disease activity (NEDA)
modified Rio score (MRS)
natalizumab
fingolimod
Online Access:https://www.mdpi.com/2077-0383/10/9/1830

Internet

https://www.mdpi.com/2077-0383/10/9/1830

Similar Items